Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Time to Sell?

Daré Bioscience, Inc. (NASDAQ:DARE) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.43 and traded as low as $3.21. Daré Bioscience shares last traded at $3.27, with a volume of 11,368 shares changing hands.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Trading Up 1.9 %

The stock has a market capitalization of $28.45 million, a P/E ratio of -5.54 and a beta of 1.28. The stock’s 50 day simple moving average is $3.24 and its 200 day simple moving average is $3.43.

Hedge Funds Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC grew its stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.